Described herein is the enantioselective synthesis of Hantzsch-type 1,4-dihydropyridines (DHPs), which are frequently contained in pharmaceuticals. Readily available symmetrical 1,4-DHPs were used as substrates, and the methyl group at the 2-or 6-position of the 1,4-DHP was selectively monobrominated by desymmetrizing enantioselective bromination. The inert CÀ H bond was converted into a versatile CÀ Br bond, which guaranteed the modification of the chiral 1,4-DHP derivatives with high efficiency. Furthermore, axially chiral 4-aryl pyridines were accessible by centralto-axial chirality conversion.The 1,4-dihydropyridines (1,4-DHPs) are widespread in both natural products and synthetic compounds with a wide range of biological activities, [1,2] of which the most important by far are the effective voltage-gated Ca 2 + (Ca v ) channel antagonists. [3] So far, many 1,4-DHPs have been synthesized worldwide and have led to numerous commercial products, such as nifedipine, nitrendipine, nisoldipine, lacidipine, felodipine, amlodipine (Scheme 1a). Among these widely prescribed drugs, amlodipine and nifedipine have been the world's bestsellers for decades. Generally, three generations of these drugs have been developed due to their different properties such as bioavailability or tissue selectivity. The easy way to change these properties was simply by altering the substituents. Meanwhile, different enantiomers exhibit different pharmacological activities or even reversal of activities [4] (Scheme 1b). For instance, racemic amlodipine is prescribed for the management of angina and hypertension. However, only (S)-amlodipine as the active moiety possesses therapeutic activity. [5] Moreover, (S)-amlodipine can avoid side effects such as acral edema, headache, and dizziness caused by racemic amlodipine. Another example is the opposite activity of the 1,4-DHP enantiomers. Whereas